Yohann Loriot

Université Paris-Sud (FR)

Research Areas

Discover Papers by Yohann Loriot

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

Publications

1131

Citations

55530

i10-index

316

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
TGFβ attenuates tumour response to PD-L1 blockade ...	2018	5597
Gut microbiome influences efficacy of PD-1–based i...	2017	5553
Abiraterone and Increased Survival in Metastatic P...	2011	4422
Atezolizumab in patients with locally advanced and...	2016	3734
Enzalutamide in Metastatic Prostate Cancer before ...	2014	3057
MPDL3280A (anti-PD-L1) treatment leads to clinical...	2014	2428
Atezolizumab as first-line treatment in cisplatin-...	2016	2221
Avelumab Maintenance Therapy for Advanced or Metas...	2020	1500
Atezolizumab versus chemotherapy in patients with ...	2017	1430
Erdafitinib in Locally Advanced or Metastatic Urot...	2019	1379

Publications

1.
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Year: 2018Citations: 5597DOI: 10.1038/nature25501
2.
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Year: 2017Citations: 5553DOI: 10.1126/science.aan3706
3.
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Year: 2011Citations: 4422DOI: 10.1056/nejmoa1014618
4.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Year: 2016Citations: 3734DOI: 10.1016/s0140-6736(16)00561-4
5.
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Year: 2014Citations: 3057DOI: 10.1056/nejmoa1405095
6.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Year: 2014Citations: 2428DOI: 10.1038/nature13904
7.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Year: 2016Citations: 2221DOI: 10.1016/s0140-6736(16)32455-2
8.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Year: 2020Citations: 1500DOI: 10.1056/nejmoa2002788
9.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Year: 2017Citations: 1430DOI: 10.1016/s0140-6736(17)33297-x
10.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Year: 2019Citations: 1379DOI: 10.1056/nejmoa1817323

About Yohann Loriot

Yohann Loriot is a researcher with 1131 publications and 55530 citations. They are affiliated with Université Paris-Sud. Their research focuses on . With an h-index of 79, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Yohann Loriot and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year